SecBot SecBot
6-K ·Filed Aug 20, 2026

BNTX

BioNTech SE
NEUTRAL
Impact 4/10
Horizonweeks Processed2mo ago SEC0001776985-26-000057
Notable filing: 6-K
Actionable Insight • Neutral

Monitor the WCLC conference (Sept 12-15, 2026) for actual clinical data readouts on pumitamig, gotistobart, and the pumitamig+elfetabart drozuntecan combination. The stock may move on data quality, but this filing itself is a routine pipeline update with no immediate catalyst.

DirectionNeutral
Confidencehigh
Horizonweeks

gotistobart

● Neutral Named in this 6-K
Impact
Phase
Phase 3
Time to market
At least 2-4 years away from potential approval, assuming positive Phase 3 data leads to regulatory filing. The PRESERVE-003 Phase 3 trial is ongoing with updated OS data due Sept 2026, but no regulatory submission has been announced.
Next catalyst
None dated

What to watchThe key near-term catalyst is the WCLC 2026 conference (Sept 12-15, 2026), where updated overall survival data from the Phase 3 PRESERVE-003 trial of gotistobart in squamous NSCLC will be presented. Positive data could drive BNTX shares higher, but gotistobart is one of several late-stage assets in BioNTech's broad pipeline, so the stock impact is unlikely to be binary.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$110.89
T+0 close · Aug 20, 2026 · via day close
Latest settled
−22.81%
T+60 · $85.60
Vs SPY
−21.73%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 20 $110.89entry
  2. T+1 · 3mo ago +5.12%α +4.71% · $116.57
  3. T+5 · 3mo ago +0.46%α −0.65% · $111.40
  4. T+20 · 2mo ago −13.37%α −13.37% · $96.06
  5. T+60 · 4d ago −22.81%α −21.73% · $85.60
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BioNTech filed a 6-K press release announcing upcoming data presentations at the IASLC 2026 World Conference on Lung Cancer (WCLC), including first global data for the novel-novel combination of pumitamig plus elfetabart drozuntecan and updated overall survival data for gotistobart from the PRESERVE-003 Phase 3 trial. The filing is a routine pipeline update with no financial data, and the actual clinical results will not be disclosed until the conference in September 2026, limiting near-term trading impact.

Key Facts

  • BioNTech will present data at WCLC 2026 (Sept 12-15) from its lung cancer pipeline, including first data for pumitamig + elfetabart drozuntecan combination and updated OS for gotistobart.
  • The filing is a curtain-raiser press release with no clinical results disclosed; actual data will be presented at the conference.
  • BioNTech has 16 ongoing lung cancer trials, including five Phase 3 and two novel-novel combination trials.
  • No financial figures, guidance, or material agreements were included in this filing.

Financial Impact

No financial figures disclosed in the filing.

Risk Factors

  • Clinical trial data may fail to meet expectations, leading to negative stock reaction at WCLC.
  • Forward-looking statements about pipeline progress are subject to regulatory and development risks.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
79% bullish (28 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001776985-26-000057
Document: form6-kwclccurtainraiser20.htm0001776985-26-000057
Document: 0001776985-26-000057-index-headers.html0001776985-26-000057
Document: 0001776985-26-000057-index.html0001776985-26-000057
Document: 0001776985-26-000057.txt0001776985-26-000057

Track record

38 reports on BNTX

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +25.10% at T+20 after the Mar 24, 2026 report. 11 of 16 went positive at some point.

Filters
  1. Nov 10, 20266d ago 6-K Neutral 4/10 Entry $87.21 Now $85.60 −1.85% settles Feb 8
  2. Nov 3, 202613d ago 6-K Neutral 5/10 No price data
  3. Nov 3, 202613d ago 6-K Neutral 5/10 No price data
  4. Nov 3, 202613d ago Press Release Neutral 5/10 Entry $86.92 Now $85.60 −1.52% settles Feb 1
  5. Oct 29, 202618d ago Institutional Cluster Mixed 3/10 Entry $89.13 Now $85.60 −3.96% settles Jan 27
  6. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $86.86 Now $85.60 −1.45% settles Jan 22
  7. Oct 26, 202621d ago 6-K Bearish 5/10 Entry $86.86 Now $85.60 +1.45% settles Jan 22
  8. Oct 26, 202621d ago Press Release Bearish 6/10 Entry $86.86 Now $85.60 +1.45% settles Jan 22
  9. Oct 25, 202622d ago Press Release Bullish 6/10 Entry $86.86 Now $85.60 −1.45% settles Jan 22
  10. Oct 22, 202625d ago 6-K Neutral 5/10 Entry $89.67 Now $85.60 −4.54% settles Jan 20
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (13h 18m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 20, 2026